NYSE:HAE Haemonetics (HAE) Stock Price, News & Analysis → Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed! (From Priority Gold) (Ad) Free HAE Stock Alerts $87.07 +0.85 (+0.99%) (As of 03:27 PM ET) Add Compare Share Share Today's Range$84.46▼$87.2350-Day Range$71.41▼$87.0552-Week Range$70.74▼$95.26Volume231,004 shsAverage Volume445,570 shsMarket Capitalization$4.42 billionP/E Ratio35.39Dividend YieldN/APrice Target$104.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Haemonetics alerts: Email Address Haemonetics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside20.9% Upside$104.67 Price TargetShort InterestBearish4.45% of Float Sold ShortDividend StrengthN/ASustainability-0.54Upright™ Environmental ScoreNews Sentiment1.22Based on 7 Articles This WeekInsider TradingN/AProj. Earnings Growth7.34%From $3.95 to $4.24 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.04 out of 5 starsMedical Sector105th out of 907 stocksSurgical & Medical Instruments Industry16th out of 96 stocks 2.3 Analyst's Opinion Consensus RatingHaemonetics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Amount of Analyst CoverageHaemonetics has only been the subject of 1 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted4.45% of the float of Haemonetics has been sold short.Short Interest Ratio / Days to CoverHaemonetics has a short interest ratio ("days to cover") of 4.7.Change versus previous monthShort interest in Haemonetics has recently increased by 9.80%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldHaemonetics does not currently pay a dividend.Dividend GrowthHaemonetics does not have a long track record of dividend growth. Previous Next 4.3 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreHaemonetics has received a 64.94% net impact score from Upright. Haemonetics seems to create the most significant positive value in categories "Taxes", "Physical diseases", and "Relationships". The positive contribution in the "Physical diseases" impact category is mostly driven by its "Computerized clinical decision support software", "Hemofilters", and "Medical technology engineering" products. See details.Environmental SustainabilityThe Environmental Impact score for Haemonetics is -0.54. Previous Next 2.9 News and Social Media Coverage News SentimentHaemonetics has a news sentiment score of 1.22. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.42 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Haemonetics this week, compared to 6 articles on an average week.Search InterestOnly 2 people have searched for HAE on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Haemonetics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Haemonetics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.79% of the stock of Haemonetics is held by insiders.Percentage Held by Institutions99.67% of the stock of Haemonetics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 2.5 Earnings and Valuation Earnings GrowthEarnings for Haemonetics are expected to grow by 7.34% in the coming year, from $3.95 to $4.24 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Haemonetics is 35.18, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 140.81.Price to Earnings Ratio vs. SectorThe P/E ratio of Haemonetics is 35.18, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 201.39.Price to Earnings Growth RatioHaemonetics has a PEG Ratio of 2.01. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioHaemonetics has a P/B Ratio of 5.34. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Priority GoldRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.Click here for your free guide About Haemonetics Stock (NYSE:HAE)Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system, and Donor360. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG, ClotPro, and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, it provides Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and VASCADE products comprising VASCADE and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot including collagen. The company sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.Read More HAE Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart HAE Stock News HeadlinesApril 22, 2024 | americanbankingnews.comHaemonetics Co. (NYSE:HAE) Expected to Earn Q1 2025 Earnings of $0.95 Per ShareApril 18, 2024 | americanbankingnews.comHaemonetics Co. (NYSE:HAE) Short Interest Down 6.4% in MarchApril 25, 2024 | Priority Gold (Ad)Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.April 18, 2024 | msn.comVivasure implants first venous patient in PerQseal device trialApril 17, 2024 | finance.yahoo.comIs Haemonetics Corporation's (NYSE:HAE) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?April 15, 2024 | americanbankingnews.comFY2026 EPS Estimates for Haemonetics Co. Cut by Barrington Research (NYSE:HAE)April 10, 2024 | finance.yahoo.comHaemonetics Sets Date for Publishing Fourth Quarter and Fiscal Year 2024 Results: May 9, 2024April 10, 2024 | prnewswire.comHaemonetics Sets Date for Publishing Fourth Quarter and Fiscal Year 2024 Results: May 9, 2024April 25, 2024 | Priority Gold (Ad)Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.April 7, 2024 | cnn.comHaemonetics CorporationApril 4, 2024 | msn.comHaemonetics gets FDA okay for TEG 6s hemostasis cartridgeApril 4, 2024 | finanznachrichten.deHaemonetics Corporation: Haemonetics Receives FDA Clearance for New TEG 6s Global Hemostasis - HN CartridgeApril 1, 2024 | finance.yahoo.comHaemonetics Corporation Completes Acquisition of Attune MedicalMarch 27, 2024 | finance.yahoo.comDoes Haemonetics (NYSE:HAE) Deserve A Spot On Your Watchlist?March 7, 2024 | finance.yahoo.comHaemonetics Corporation (NYSE:HAE) Shares Could Be 35% Below Their Intrinsic Value EstimateMarch 6, 2024 | bizjournals.comAttune Medical acquired by Massachusetts-based Haemonetics for $160 millionMarch 5, 2024 | bizjournals.comHaemonetics to buy Chicago medical device company for $160 millionMarch 5, 2024 | finanznachrichten.deHaemonetics Corporation: Haemonetics Announces Definitive Agreement to Acquire Attune MedicalMarch 5, 2024 | marketwatch.comHaemonetics to Buy Attune Medical for $160 Million >HAEMarch 5, 2024 | msn.comHaemonetics to buy Attune Medical for $160MMarch 5, 2024 | prnewswire.comHaemonetics Announces Definitive Agreement to Acquire Attune MedicalFebruary 22, 2024 | wsj.comHaemonetics Corp.February 21, 2024 | finance.yahoo.comHaemonetics to Present at Citi's 2024 Unplugged Medtech and Life Sciences Access DayFebruary 21, 2024 | finance.yahoo.comHaemonetics to Present at Raymond James 45th Annual Institutional Investors ConferenceFebruary 21, 2024 | prnewswire.comHaemonetics to Present at Raymond James 45th Annual Institutional Investors ConferenceFebruary 21, 2024 | prnewswire.comHaemonetics to Present at Citi's 2024 Unplugged Medtech and Life Sciences Access DayFebruary 9, 2024 | finance.yahoo.comHaemonetics (HAE) Q3 Earnings Top Estimates, 2024 View RaisedSee More Headlines Receive HAE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Haemonetics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/08/2024Today4/25/2024Next Earnings (Confirmed)5/09/2024Fiscal Year End3/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Surgical & medical instruments Sub-IndustryHealth Care Supplies Current SymbolNYSE:HAE CUSIP40502410 CIK313143 Webwww.haemonetics.com Phone(781) 848-7100Fax781-848-5106Employees3,034Year Founded1971Price Target and Rating Average Stock Price Target$104.67 High Stock Price Target$115.00 Low Stock Price Target$94.00 Potential Upside/Downside+22.3%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)$2.46 Trailing P/E Ratio34.80 Forward P/E Ratio21.67 P/E Growth2.01Net Income$115.40 million Net Margins9.97% Pretax Margin12.68% Return on Equity22.37% Return on Assets9.71% Debt Debt-to-Equity Ratio0.91 Current Ratio2.92 Quick Ratio1.76 Sales & Book Value Annual Sales$1.17 billion Price / Sales3.72 Cash Flow$5.01 per share Price / Cash Flow17.10 Book Value$16.22 per share Price / Book5.28Miscellaneous Outstanding Shares50,790,000Free Float49,877,000Market Cap$4.35 billion OptionableOptionable Beta0.36 Social Links The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesMr. Christopher A. Simon (Age 60)CEO, President & Director Comp: $3.26MMr. James C. D'Arecca CPA (Age 53)CFO, Executive VP & Financial Officer Comp: $1.8MMs. Anila Lingamneni (Age 56)Executive VP & CTO Comp: $1.09MMs. Michelle L. Basil (Age 52)Executive VP, General Counsel & Secretary Comp: $1.26MMr. Josep Lluis Llorens (Age 62)Executive Vice President of Global Manufacturing & Supply Chain Comp: $1.11MMs. Farris Maryanne Maunsell (Age 49)VP, Chief Accounting Officer & Principal Accounting Officer Ms. Olga GuyetteSenior Director of Investor RelationsMr. Rajeev VarmaSenior Vice President of Strategy & Corporate DevelopmentMs. Laurie A. Miller (Age 51)Senior VP & Chief Human Resources Officer Dr. Jan Hartmann M.D.Senior VP & Chief Medical OfficerMore ExecutivesKey CompetitorsMerit Medical SystemsNASDAQ:MMSIICU MedicalNASDAQ:ICUIiRhythm TechnologiesNASDAQ:IRTCAxonicsNASDAQ:AXNXPROCEPT BioRoboticsNASDAQ:PRCTView All CompetitorsInsiders & InstitutionsAssenagon Asset Management S.A.Bought 12,970 shares on 4/24/2024Ownership: 0.026%Keene & Associates Inc.Bought 1,219 shares on 4/24/2024Ownership: 0.020%Rice Hall James & Associates LLCSold 9,157 shares on 4/23/2024Ownership: 0.094%Amalgamated BankSold 5,508 shares on 4/23/2024Ownership: 0.052%Louisiana State Employees Retirement SystemBought 300 shares on 4/23/2024Ownership: 0.029%View All Insider TransactionsView All Institutional Transactions HAE Stock Analysis - Frequently Asked Questions Should I buy or sell Haemonetics stock right now? 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Haemonetics in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" HAE shares. View HAE analyst ratings or view top-rated stocks. What is Haemonetics' stock price target for 2024? 2 brokerages have issued twelve-month price targets for Haemonetics' stock. Their HAE share price targets range from $94.00 to $115.00. On average, they predict the company's share price to reach $104.67 in the next year. This suggests a possible upside of 20.9% from the stock's current price. View analysts price targets for HAE or view top-rated stocks among Wall Street analysts. How have HAE shares performed in 2024? Haemonetics' stock was trading at $85.51 at the start of the year. Since then, HAE stock has increased by 1.2% and is now trading at $86.55. View the best growth stocks for 2024 here. Are investors shorting Haemonetics? Haemonetics saw a increase in short interest in the month of April. As of April 15th, there was short interest totaling 2,240,000 shares, an increase of 9.8% from the March 31st total of 2,040,000 shares. Based on an average trading volume of 476,900 shares, the days-to-cover ratio is presently 4.7 days. Approximately 4.5% of the shares of the company are short sold. View Haemonetics' Short Interest. When is Haemonetics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our HAE earnings forecast. How can I listen to Haemonetics' earnings call? Haemonetics will be holding an earnings conference call on Thursday, May 9th at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link. How were Haemonetics' earnings last quarter? Haemonetics Co. (NYSE:HAE) issued its quarterly earnings results on Thursday, February, 8th. The medical instruments supplier reported $1.04 earnings per share for the quarter, topping analysts' consensus estimates of $0.94 by $0.10. The medical instruments supplier earned $336.20 million during the quarter, compared to analyst estimates of $320.84 million. Haemonetics had a net margin of 9.97% and a trailing twelve-month return on equity of 22.37%. The company's quarterly revenue was up 10.1% compared to the same quarter last year. During the same quarter last year, the business earned $0.85 earnings per share. What ETFs hold Haemonetics' stock? ETFs with the largest weight of Haemonetics (NYSE:HAE) stock in their portfolio include SPDR S&P Health Care Equipment ETF (XHE), Harbor Health Care ETF (MEDI), AlphaMark Actively Managed Small Cap ETF (SMCP), Amplify Etho Climate Leadership U.S. ETF (ETHO) and VictoryShares US Small Cap Volatility Wtd (CSA).IQ Chaikin U.S. Small Cap ETF (CSML). What guidance has Haemonetics issued on next quarter's earnings? Haemonetics updated its FY24 earnings guidance on Thursday, February, 8th. The company provided earnings per share guidance of $3.90-4.00 for the period, compared to the consensus EPS estimate of $3.89. The company issued revenue guidance of ~$1.28-1.31 billion, compared to the consensus revenue estimate of $1.27 billion. What is Christopher Simon's approval rating as Haemonetics' CEO? 48 employees have rated Haemonetics Chief Executive Officer Christopher Simon on Glassdoor.com. Christopher Simon has an approval rating of 63% among the company's employees. This puts Christopher Simon in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Haemonetics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Haemonetics investors own include NVIDIA (NVDA), Micron Technology (MU), Johnson & Johnson (JNJ), AbbVie (ABBV), Citigroup (C), Align Technology (ALGN), Chipotle Mexican Grill (CMG), Netflix (NFLX) and Pfizer (PFE). Who are Haemonetics' major shareholders? Haemonetics' stock is owned by a number of retail and institutional investors. Top institutional investors include Allspring Global Investments Holdings LLC (0.99%), Rice Hall James & Associates LLC (0.09%), Los Angeles Capital Management LLC (0.05%), Amalgamated Bank (0.05%), CWM LLC (0.05%) and Dynamic Advisor Solutions LLC (0.04%). Insiders that own company stock include Anila Lingamneni, Christopher Simon, Dan Goldstein, Jacqueline Scanlan, Josep Llorens, Laurie A Miller, Mark W Kroll, Mark W Kroll, Michelle L Basil, Michelle L Basil, Stewart W Strong and William P Mr Burke. View institutional ownership trends. How do I buy shares of Haemonetics? Shares of HAE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSE:HAE) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldHe Is Giving Away BitcoinCrypto Swap ProfitsYour Money is Not SafeAmerican Alternative Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Haemonetics Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
